NASDAQ$TECX
Tectonic Therapeutic Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
AVROBIO reported a net loss for Q3 2022, driven by a reduction in research and development expenses. The company highlighted progress in its gene therapy programs, including rare pediatric disease designations for Gaucher disease and cystinosis.
AVROBIO reported a net loss of $23.0 million for the third quarter of 2022, compared to a net loss of $32.6 million for the same period in 2021. The decrease was attributed to a reduction in research and development expenses. The company's cash and cash equivalents as of September 30, 2022, are expected to fund operating expenses and capital expenditure requirements into the first quarter of 2024.
- Patient dosing was completed in a collaborator-sponsored Phase 1/2 clinical trial for cystinosis.
- Rare pediatric disease designations were received for Gaucher disease and cystinosis investigational gene therapies.
- A comprehensive Gaucher disease program update is planned for December 7.
- A clinical trial application for Hunter syndrome was approved by MHRA.
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2022
-1.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro